Trial: 201612068

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
(ALLELE Study)

Phase

III

Principal Investigator

Ghobadi, Armin

Disease Site

Other Hematopoietic

Learn more about this study at: clinicaltrials.gov